Immediate Access for the Terminally Ill Act

The Immediate Access for the Terminally Ill Act, S3648, referred to the Committee on Finance, establishes a federal right for terminally ill patients to access investigational drugs, biologics, and devices that have completed a Phase 1 clinical trial. This bill bypasses the traditional FDA approval process for this specific patient population, directly expanding the addressable market for experimental therapies. Pharmaceutical companies with drugs in late-stage clinical trials stand to gain immediate revenue streams from these therapies, which would otherwise be years away from market. The money trail for this legislation flows directly to pharmaceutical and biotechnology companies. Patients or their insurers will pay for these investigational treatments, creating a new revenue channel for companies. There are no direct government appropriations or grants associated with this bill; rather, it facilitates direct-to-consumer sales of unapproved, but Phase 1-tested, drugs. Companies like Amgen ($AMGN), Gilead Sciences ($GILD), Biogen ($BIIB), Eli Lilly ($LLY), and Pfizer ($PFE), which have extensive pipelines of drugs for life-threatening conditions, are positioned to capture this new market segment. Historically, similar 'Right to Try' legislation has been enacted at the state level and federally. The federal Right to Try Act of 2018, signed into law in May 2018, allowed terminally ill patients to access unapproved treatments. While the 2018 act did not immediately trigger massive stock movements due to its limited scope and implementation challenges, it established the precedent for expanding access. This new bill, S3648, builds upon that foundation by potentially streamlining the process and increasing utilization, thus creating a more direct and measurable revenue impact for pharmaceutical companies. For example, after the 2018 act, companies with relevant pipelines saw modest, sustained interest rather than immediate spikes, as the market assessed the practical implications. Specific winners include large pharmaceutical companies with robust oncology and rare disease pipelines, such as Amgen ($AMGN), Gilead Sciences ($GILD), Biogen ($BIIB), Eli Lilly ($LLY), and Pfizer ($PFE). These companies have the infrastructure to manage expanded access programs and the portfolio of late-stage drugs that would qualify. There are no clear losers from this legislation; it primarily creates new market opportunities. The timeline involves the bill's progression through the Senate Finance Committee. If it passes committee, it moves to a full Senate vote. Given its 'right to try' nature, it has a high probability of bipartisan support, suggesting a potential passage within the next 12-18 months. This bill does not appropriate funds but rather alters regulatory access, creating a new revenue stream for pharmaceutical companies. The impact is direct: companies can monetize drugs earlier. The legislative stage is early (referred to committee), but the historical precedent of 'Right to Try' legislation suggests a path forward. The sector size of healthcare, particularly pharmaceuticals, is substantial, meaning even a niche market expansion can yield significant revenue for specific companies.